Johnson & Johnson (JNJ) Stock
Diversified healthcare giant with medicines devices and consumer products. Here's the price, business snapshot, and what's worth knowing about Johnson & Johnson in June 2026.
Johnson & Johnson (JNJ) is a large, diversified healthcare company operating across pharmaceuticals, medical devices and consumer health products. With a market capitalisation of about $462.11 billion, it mixes steady cash-generative consumer brands with higher-growth prescription medicines and device franchises. Investors often watch J&J for its scale, research and development pipeline, global reach and long record of dividend payments, but the company also faces patent expiries, regulatory scrutiny, litigation risk and competition that can affect earnings. Financial performance may be influenced by new product approvals, M&A activity and macroeconomic conditions. This summary is general, educational information only and not personal advice — investing carries risk and past performance is not a reliable guide to future results. Consider consulting a financial professional about suitability for your circumstances.
Why It’s Moving
JNJ slips as analysts flag downside risk despite steady defensive demand
- Analyst sentiment remains guarded, with the stock still trading under a cloud of downside-risk calls that suggest expectations are stretched relative to near-term growth.
- Investors are leaning on J&J’s defensive healthcare profile, but that support is being offset by concerns about whether the company can deliver enough momentum to justify current positioning.
- In the absence of a major earnings surprise or big product update this week, the stock’s move is being driven more by valuation debate and broader caution around large-cap healthcare names.
JNJ slips as analysts flag downside risk despite steady defensive demand
- Analyst sentiment remains guarded, with the stock still trading under a cloud of downside-risk calls that suggest expectations are stretched relative to near-term growth.
- Investors are leaning on J&J’s defensive healthcare profile, but that support is being offset by concerns about whether the company can deliver enough momentum to justify current positioning.
- In the absence of a major earnings surprise or big product update this week, the stock’s move is being driven more by valuation debate and broader caution around large-cap healthcare names.
When is the next earnings date for Johnson & Johnson (JNJ)?
Johnson & Johnson’s next earnings date is expected to be July 15, 2026, with the company reporting before market open. The release should cover fiscal Q2 2026, which corresponds to the quarter ending June 2026. This is consistent with JNJ’s typical mid-July reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Johnson & Johnson's stock, with a target price suggesting growth potential.
Financial Health
Johnson & Johnson is generating strong profits and cash flow, showing solid overall financial performance.
Dividend
Johnson & Johnson's dividend yield of 2.16% offers a moderate return for dividend-seeking investors. If you invested $1000 you would be paid $21.60 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring JNJ
Blue-Chip Tech Stocks (After Buffett's Apple Regret)
Warren Buffett has publicly regretted selling Apple shares too early, indicating Berkshire Hathaway would buy more if prices drop significantly. This creates a unique moment to explore value-oriented tech stocks and supply chain partners that might present better current entry points.
Published: 2 April 2026
Explore BasketSemiconductor Patent Disputes (Foundry Market Impact)
GlobalFoundries has launched a major patent infringement lawsuit against Tower Semiconductor to protect its proprietary manufacturing technologies. This legal dispute underscores the growing importance of intellectual property enforcement in the competitive semiconductor sector, creating opportunities for rival foundries and IP-focused tech firms.
Published: 27 March 2026
Explore BasketDefensive Equities | Risks in a Slowing Labour Market
After the U.S. economy unexpectedly shed 92,000 jobs in February, investors are seeking shelter from the resulting market volatility. This collection features resilient, non-cyclical companies that historically maintain their value and offer stability during periods of economic deceleration.
Published: 9 March 2026
Explore BasketBiotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketFed Division: Fortress Balance Sheets Explained
The Federal Reserve is showing a rare public division on whether to raise, lower, or hold interest rates, creating uncertainty for the markets. This theme focuses on investing in companies with strong financial health that are better equipped to handle the market volatility resulting from unpredictable monetary policy.
Published: 19 February 2026
Explore BasketBlue-Chip Stocks Rally Beyond 50K Mark in 2025
The Dow Jones Industrial Average's historic breach of the 50,000 mark highlights a powerful rebound in the market, led by blue-chip stocks. This event signals a potential investment opportunity in established companies within the financial and industrial sectors that are demonstrating strength and stability.
Published: 7 February 2026
Explore BasketFlight to Safety Assets | Fed Uncertainty Overview
A landmark Supreme Court case is set to determine whether the president can fire a Federal Reserve governor, placing the central bank's political independence at a critical juncture. This event could spur market volatility, potentially benefiting safe-haven assets and defensive stocks that investors turn to in times of uncertainty.
Published: 21 January 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketCancer Therapies: What's Next After 100% Response Rate
Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published: 7 December 2025
Explore BasketGlobal Medtech UAE Healthcare Investment Basket 2025
The United Arab Emirates is making significant investments to upgrade its medical infrastructure, aiming to become a global healthcare destination. This basket provides exposure to the international US and EU-listed companies in pharmaceuticals, medtech, and digital health that supply this ambitious national project.
Published: 12 November 2025
Explore BasketHealthcare Innovation Brazil Investment Theme 2025
Brazil is ramping up investment to enhance its healthcare quality and access, creating significant opportunities for innovation. This basket offers exposure to key US and EU-listed companies providing the medical devices, software, and biotech research driving this transformation.
Published: 30 October 2025
Explore BasketDow Jones Stocks (Blue-Chip) for Brazilian Investors
For Brazilians seeking portfolio stability away from domestic market volatility, US blue-chip companies offer exposure to global economic leaders. This basket contains shares of established, US-listed industrial and technology firms that form the Dow Jones Industrial Average.
Published: 14 October 2025
Explore BasketHealthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: 14 October 2025
Explore BasketAlternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: 13 October 2025
Explore BasketChild Investment Plans Brazil Global Brands 2025
Brazilian families seeking long-term financial stability for the next generation may find opportunities in established international companies. This basket provides exposure through US and EU-listed stocks of globally recognized consumer, technology, and financial brands.
Published: 8 October 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: 23 September 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: 22 September 2025
Explore BasketJohnson & Johnson (Healthcare Diversification)
As Nigeria's population seeks stable growth opportunities, the global healthcare sector offers a compelling theme for portfolio diversification. This basket provides exposure through a collection of US and EU-listed industry leaders in pharmaceuticals, medical devices, and consumer health.
Published: 16 September 2025
Explore BasketPharma Investment Basket Explained (Eli Lilly+)
Nigeria's growing population is increasingly seeking exposure to global health advancements, particularly from leading pharmaceutical innovators. This basket provides potential exposure to this trend through a collection of US and EU-listed pharmaceutical, biotechnology, and healthcare supply chain companies.
Published: 11 September 2025
Explore BasketNext-Generation Antibiotic Innovators
With the FDA granting priority review to GSK's new oral antibiotic for gonorrhea, a new front has opened in the fight against drug-resistant bacteria. This theme focuses on the biotechnology companies developing the next generation of antibiotics to address this critical and growing public health need.
Published: 12 August 2025
Explore BasketPowering The AI Supercluster
OpenAI and Oracle are partnering on a $500 billion project to build a massive AI supercluster in the U.S. This historic infrastructure investment creates a significant opportunity for companies that supply the essential power, cooling, and construction services needed to support this build-out.
Published: 23 July 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: 15 July 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: 3 July 2025
Explore BasketSleep Well At Night Portfolio
A collection of premium defensive stocks expertly selected by our analysts to help protect your investments during market turbulence. These industry giants offer stability through consistent earnings, reliable dividends, and proven resilience in any economic climate.
Published: 18 June 2025
Explore BasketEasy Starter Portfolio
Begin your investment journey confidently with this smartly designed collection of stocks. Our professional analysts have carefully selected these assets to give you instant global diversification paired with world-leading companies, creating the perfect foundation for long-term growth.
Published: 18 June 2025
Explore BasketGlobal Giants
Own a piece of the world's most powerful companies in one portfolio. These industry titans have been carefully selected by our analysts for their market dominance, stability, and long-term growth potential.
Published: 18 June 2025
Explore BasketMarket Indecision
Find refuge from market volatility with these carefully selected companies providing essential goods and services. Our professional analysts have handpicked high-quality, dividend-paying stocks in defensive sectors that offer stability when economic futures look uncertain.
Published: 18 June 2025
Explore BasketMoat Wideners
These companies are building unbeatable competitive advantages that competitors simply can't match. Our analysts have carefully selected businesses that prioritize long-term market dominance over quick profits, creating exceptional durability and growth potential.
Published: 17 June 2025
Explore BasketBest In Class
Meet the true champions of the market. These carefully selected stocks represent the single most influential company in each economic sector, chosen by expert analysts for their market dominance and enduring competitive advantages.
Published: 17 June 2025
Explore BasketProfit Sharers
These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.
Published: 17 June 2025
Explore BasketPatient Builders
Companies that create lasting value through quality and customer trust rather than chasing quick profits. This carefully curated collection showcases market leaders who've proven that patient, sustainable growth leads to superior long-term returns.
Published: 17 June 2025
Explore BasketBig Payout Candidates
This carefully selected group of companies is flush with cash and primed to reward investors. Each stock has been handpicked by our analysts for its potential to deliver exceptional returns through special dividends or substantial buybacks above their regular shareholder payouts.
Published: 17 June 2025
Explore BasketMercury Retrograde
A collection of stable, essential businesses selected by financial experts to help protect your investments during market turbulence. These companies provide the goods and services people need every day, regardless of economic conditions.
Published: 17 June 2025
Explore BasketMind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: 17 June 2025
Explore BasketBeauty
These beauty stocks represent leading companies in skincare, haircare, and makeup. Carefully selected by our analysts, these investments offer exposure to a growing global industry expected to reach $716.6 billion by 2025.
Published: 21 May 2025
Explore BasketLow Volatility Stocks
Are you feeling seasick? Sail through calmer waters with these lower volatility investments. These handpicked stocks were carefully selected by our analysts for their history of stability and potential for consistent returns over time.
Published: 21 May 2025
Explore BasketIncredibly Profitable Stocks
Invest in some of the world's most profitable companies, carefully selected by our professional analysts. These established market leaders have proven track records of strong financial performance and global influence.
Published: 19 May 2025
Explore BasketLargest U.S Stocks
Everything is bigger in America! This collection features some of the world's largest companies, carefully selected by our professional analysts. From tech giants to energy behemoths, these stocks represent the backbone of the American economy.
Published: 17 May 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: 6 May 2025
Explore BasketTop Dividend Paying Stocks
These reliable companies have a proven track record of sharing profits with investors through regular dividend payments. Carefully selected by our professional analysts, these stocks offer the potential for both steady income and long-term growth.
Published: 3 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diversified revenue base
Pharmaceuticals, devices and consumer products spread revenue sources, which can smooth cycles — though divisions face different risks and growth prospects.
R&D and pipeline
A strong research pipeline can drive future growth if approvals succeed, but clinical setbacks or regulatory delays can weigh on returns.
Global footprint
Sales across many markets provide scale and resilience, yet global regulation, litigation and supply-chain risks can affect performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
